MetaCap

Johnson & Johnson (JNJ)

NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD

270.47+3.33 (+1.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

JNJ stock chart

Technical analysis

Key statistics

All statistics
Market cap
$651.11B
Dividend yield
1.95% ($5.28)
Ex-dividend date
Aug 25, 2026
52-week range
199.91 – 290.25
Day range
269.47 – 272.48
Volume / Avg
11.92M / 7.29M
Beta
—
Next earnings
Jan 26, 2027

52-week range

$199.91$290.25

JNJ stock today

Shares of Johnson & Johnson (JNJ) finished higher on Nov 20 at $270.47, a gain of 1.25% or $3.33 per share, versus the S&P 500's 3.70% decline. At this level, JNJ sits in the middle of its 52-week range of $199.91 to $290.25: 6.8% below the high, set on Nov 16, 2026 and 35.3% above the low. JNJ is up 30.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 32.6%.

At 41.0x trailing earnings, Johnson & Johnson trades above the peer-group median of 35.8x. Its forward P/E of 23.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Johnson & Johnson's next earnings report is expected on Jan 26, 2027. Johnson & Johnson pays an annual dividend of $5.28 per share, a 1.95% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Johnson & Johnson

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joaquin Duato
Headquarters
New Brunswick, NJ
Employees
138,200
Website
jnj.com

Financial highlights

Full financials

In fiscal 2025, Johnson & Johnson generated $94.19 billion in revenue, up 6.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $26.80 billion (+90.6% year over year), for a net margin of 28.5% versus a median of 22.4% in the prior 5 years. Gross margin was 67.9% (down from 69.1%).

Johnson & Johnson annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$94.19B$88.82B$85.16B$79.99B$78.74B
Growth+6.05%+4.30%+6.46%+1.59%-4.65%
Net income$26.80B$14.07B$35.15B$17.94B$20.88B
EPS (diluted)$11.03$5.79$13.72$6.73$7.81

Analyst forecast

Forecast

Consensus (23 analysts)

buy

Avg. price target

$279.41+3.31%

  • Strong buy 5
  • Buy 11
  • Hold 6
  • Sell 1
  • Strong sell 0

Target range

Low $190.00High $320.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Jan 26, 2027
Last reported (Sep/2026)
Oct 13, 2026
EPS actual vs est.
$2.59 vs $2.53
Surprise
+2.37%

Dividends

Dividend history
Annual dividend
$5.28
Last payment
$1.34
Ex-dividend date
Aug 25, 2026

JNJ news

All JNJ news

Johnson & Johnson peers

Health Care sector
JNJ peer companies
CompanyPrice% ChgMarket capCompare
ABBVAbbVie Inc.286.20+0.94%$505.89Bvs JNJ
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs JNJ
NVSNovartis AG150.47-0.50%$284.18Bvs JNJ
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs JNJ
ABTAbbott Laboratories103.00-0.84%$178.39Bvs JNJ
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs JNJ
PFEPfizer Inc.27.40-0.51%$156.18Bvs JNJ
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs JNJ

Indexes, lists and sector

Johnson & Johnson stock FAQ

What is Johnson & Johnson's stock price today?

JNJ last traded at $270.47 as of Nov 20, 4:00 PM EST, up 1.25% on the day. Prices are delayed at least 15 minutes.

Does Johnson & Johnson pay a dividend?

Yes. Johnson & Johnson pays $5.28 per share annually, a 1.95% yield. The most recent dividend of $1.34 had an ex-dividend date of Aug 25, 2026.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is expected to report earnings on Tuesday, January 26, 2027.

What is JNJ's P/E ratio?

JNJ trades at a trailing P/E ratio of 41.04 and a forward P/E of 23.29, compared with a median of 35.8 for its closest peers.

Is Johnson & Johnson in the S&P 500?

Yes. Johnson & Johnson (JNJ) is a constituent of the S&P 500 index.

Who is Johnson & Johnson's CEO?

Mr. Joaquin Duato is the chief executive officer of Johnson & Johnson, which has about 138,200 employees.

Has JNJ ever split its stock?

Yes. The most recent JNJ stock split was a 2-for-1 split on Jun 13, 2001, one of 6 splits on record.

Compare JNJ